Topical bevacizumab for corneal neovascularization after penetrating keratoplasty.
OBJECTIVE
To evaluate the efficacy of topical bevacizumab for corneal neovascularization in graft rejection.


METHODS
A 55-year-old man presented with corneal neovascularization and graft rejection 6 months following penetrating keratoplasty (triple procedure) in the left eye. His best-corrected visual acuity (BCVA) was counting fingers at 1 meter. He was administered topical bevacizumab (4 mg/4 mL) in a dose of one drop twice a day for 15 days. No adjunct therapy was given during bevacizumab administration.


RESULTS
After 1 month, his BCVA improved to 20/120. Corneal vascularization and stromal haze regressed. After 6 months, his BCVA improved to 20/60 with further regression in corneal vascularization and stromal haze. At 9-month follow-up, he maintained BCVA of 20/60.


CONCLUSIONS
Short-term topical bevacizumab therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty.
Saxena
Sandeep
S
Department of Ophthalmology, CSM Medical University (Erstwhile King George's Medical University), Lucknow - India. sandeepsaxena2020@yahoo.com
Kishore
Poonam
P
Pandey
Sukant
S
Khattri
Mohit
M
Kumar
Dipak
D
D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D006084:Graft Rejection / Q000209:etiology*; D006801:Humans; D015948:Keratoplasty, Penetrating / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab